"ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF RELAPSING, NON-SEVERE, GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) (ABROGATE)."

Registry ID

5527

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

UNIVERSITY OF SOUTH FLORIDA

Start date

2015-05-30

Last update

2015-05-07

Conditions

• POLYANGITIS
• GRANULOMATOSIS

Related clinical trials

• A PHASE 1/2 STUDY EVALUATING GENE THERAPY BY TRANSPLANTATION OF AUTOLOGOUS CD34+ STEM CELLS MODIFIED EX VIVO USING PRIME EDITING (PM359) IN PARTICIPANTS WITH AUTOSOMAL RECESSIVE CHRONIC GRANULOMATOUS DISEASE DUE TO MUTATIONS IN THE NCF1 GENE
• 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTI-CENTRE, NON-INFERIORITY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB COMPARED WITH MEPOLIZUMAB IN ADULTS WITH RELAPSING OR REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) RECEIVING STANDARD OF CARE (SOC) THERAPY
• A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED 52-WEEK STUDY WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB COMPARED TO MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) IN PATIENTS RECEIVING STANDARD OF CARE THERAPY

View on source registry